It is time to move forward into the era of Theranostics

Abstract Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy wi...

Full description

Bibliographic Details
Main Authors: Hojjat Ahmadzadehfar, Markus Essler
Format: Article
Language:English
Published: SpringerOpen 2018-01-01
Series:EJNMMI Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13550-018-0364-x
_version_ 1819068613293768704
author Hojjat Ahmadzadehfar
Markus Essler
author_facet Hojjat Ahmadzadehfar
Markus Essler
author_sort Hojjat Ahmadzadehfar
collection DOAJ
description Abstract Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.
first_indexed 2024-12-21T16:36:56Z
format Article
id doaj.art-7c422f9dcf1249e495d102bc4b4036f7
institution Directory Open Access Journal
issn 2191-219X
language English
last_indexed 2024-12-21T16:36:56Z
publishDate 2018-01-01
publisher SpringerOpen
record_format Article
series EJNMMI Research
spelling doaj.art-7c422f9dcf1249e495d102bc4b4036f72022-12-21T18:57:12ZengSpringerOpenEJNMMI Research2191-219X2018-01-01811210.1186/s13550-018-0364-xIt is time to move forward into the era of TheranosticsHojjat Ahmadzadehfar0Markus Essler1Department of Nuclear Medicine, University Hospital BonnDepartment of Nuclear Medicine, University Hospital BonnAbstract Radionuclide therapy, which until 15 years ago included only a few approved therapies, is gaining importance in the treatment of various malignancies. The future of oncology will not be limited to surgery, chemo-, antibody therapies or external radiation; it will include targeted therapy with radionuclides, which will become the standard of care for a variety of malignant diseases in combination or as an alternative to other therapies. Therefore there is a need to train Nuclear Oncologists, who are able to approach oncological diseases, promote development of radiopharmacy, understand the biology of radionuclide treatment, apply radionuclide treatments and be able to use molecular imaging such as PET/CT and SPECT/CT for treatment planning and dosimetry.http://link.springer.com/article/10.1186/s13550-018-0364-xTheranosticsRadionuclide therapyOncologyFellowship
spellingShingle Hojjat Ahmadzadehfar
Markus Essler
It is time to move forward into the era of Theranostics
EJNMMI Research
Theranostics
Radionuclide therapy
Oncology
Fellowship
title It is time to move forward into the era of Theranostics
title_full It is time to move forward into the era of Theranostics
title_fullStr It is time to move forward into the era of Theranostics
title_full_unstemmed It is time to move forward into the era of Theranostics
title_short It is time to move forward into the era of Theranostics
title_sort it is time to move forward into the era of theranostics
topic Theranostics
Radionuclide therapy
Oncology
Fellowship
url http://link.springer.com/article/10.1186/s13550-018-0364-x
work_keys_str_mv AT hojjatahmadzadehfar itistimetomoveforwardintotheeraoftheranostics
AT markusessler itistimetomoveforwardintotheeraoftheranostics